Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

AstraZeneca AZ

AZ starts pursuit of lung cancer indication for Imfinzi

And its EGFR inhibitor Tagrisso picks up US breakthrough status

ABPI London offices

ABPI bid to overturn NICE’s budget impact rules fails

One in five new medicines would have been affected by the rejected policy

- PMLiVE

Janssen’s Imbruvica fails to win NICE backing in lymphoma

But the agency recommends it on the CDF for another type of cancer

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

Pegasus strengthens its Pharma and Life Sciences division

Appoints three new team members to join its Northern base

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

- PMLiVE

Packing a punch in multichannel communications

Creating a more creatively robust and integrated multichannel campaign

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links